239 related articles for article (PubMed ID: 25462248)
1. 1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
Liu YM; Lee HY; Chen CH; Lee CH; Wang LT; Pan SL; Lai MJ; Yeh TK; Liou JP
Eur J Med Chem; 2015 Jan; 89():320-30. PubMed ID: 25462248
[TBL] [Abstract][Full Text] [Related]
2. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
3. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
4. Quinolone-based HDAC inhibitors.
Balasubramanian G; Kilambi N; Rathinasamy S; Rajendran P; Narayanan S; Rajagopal S
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):555-62. PubMed ID: 25019596
[TBL] [Abstract][Full Text] [Related]
5. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
[TBL] [Abstract][Full Text] [Related]
6. Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.
Angibaud P; Van Emelen K; Decrane L; van Brandt S; Ten Holte P; Pilatte I; Roux B; Poncelet V; Speybrouck D; Queguiner L; Gaurrand S; Mariën A; Floren W; Janssen L; Verdonck M; van Dun J; van Gompel J; Gilissen R; Mackie C; Du Jardin M; Peeters J; Noppe M; Van Hijfte L; Freyne E; Page M; Janicot M; Arts J
Bioorg Med Chem Lett; 2010 Jan; 20(1):294-8. PubMed ID: 19906529
[TBL] [Abstract][Full Text] [Related]
7. Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
Lee HY; Tsai AC; Chen MC; Shen PJ; Cheng YC; Kuo CC; Pan SL; Liu YM; Liu JF; Yeh TK; Wang JC; Chang CY; Chang JY; Liou JP
J Med Chem; 2014 May; 57(10):4009-22. PubMed ID: 24766560
[TBL] [Abstract][Full Text] [Related]
8. 2-(Phenylsulfonyl)quinoline N-hydroxyacrylamides as potent anticancer agents inhibiting histone deacetylase.
Lee HY; Chang CY; Su CJ; Huang HL; Mehndiratta S; Chao YH; Hsu CM; Kumar S; Sung TY; Huang YZ; Li YH; Yang CR; Liou JP
Eur J Med Chem; 2016 Oct; 122():92-101. PubMed ID: 27344487
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
Cai X; Zhai HX; Wang J; Forrester J; Qu H; Yin L; Lai CJ; Bao R; Qian C
J Med Chem; 2010 Mar; 53(5):2000-9. PubMed ID: 20143778
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.
Chen CH; Lee CH; Liou JP; Teng CM; Pan SL
Oncotarget; 2015 Nov; 6(34):35991-6002. PubMed ID: 26462017
[TBL] [Abstract][Full Text] [Related]
11. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
[TBL] [Abstract][Full Text] [Related]
12. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
Cho M; Choi E; Kim JH; Kim H; Kim HM; Lee JI; Hwang KC; Kim HJ; Han G
ChemMedChem; 2014 Mar; 9(3):649-56. PubMed ID: 24376239
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents.
Cheng J; Qin J; Guo S; Qiu H; Zhong Y
Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indoles as potent histone deacetylase inhibitors with antitumor activity in vivo.
Lai MJ; Huang HL; Pan SL; Liu YM; Peng CY; Lee HY; Yeh TK; Huang PH; Teng CM; Chen CS; Chuang HY; Liou JP
J Med Chem; 2012 Apr; 55(8):3777-91. PubMed ID: 22439863
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
[TBL] [Abstract][Full Text] [Related]
17. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
Li X; Hou J; Li X; Jiang Y; Liu X; Mu W; Jin Y; Zhang Y; Xu W
Eur J Med Chem; 2015 Jan; 89():628-37. PubMed ID: 25462271
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis.
Huang YC; Huang FI; Mehndiratta S; Lai SC; Liou JP; Yang CR
Oncotarget; 2015 Jul; 6(21):18590-601. PubMed ID: 26087180
[TBL] [Abstract][Full Text] [Related]
19. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
[TBL] [Abstract][Full Text] [Related]
20. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
